{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:03:19Z","timestamp":1785301399313,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This retrospective, single-center cohort study aimed to compare clinical outcomes, including time to minimal manifestations (MM)\u2014defined as the absence of functional limitations from MG symptoms in daily activities, even with mild muscle weakness on examination\u2014or better status, between patients aged \u226570\u202fyears with MG treated with PSL alone or with calcineurin inhibitors (CNIs), and those treated with CNI alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Twelve patients with acetylcholine receptor antibody (AChR-Ab)-positive MG aged \u226570\u202fyears were included (the PSL group,\n                      <jats:italic>n<\/jats:italic>\n                      =\u202f7; the CNIs group,\n                      <jats:italic>n<\/jats:italic>\n                      =\u202f5). Changes in the MG Activities of Daily Living scale (MG-ADL) and Quantitative MG (QMG) scores from admission to discharge were evaluated using least-squares mean estimates. Longitudinal changes in AChR-Ab titers over one year were analyzed using a mixed-effects model for repeated measures. The time to MM was assessed using Kaplan\u2013Meier analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The MG-ADL scores improved in both groups, with a greater change in the PSL group. QMG scores improved in the PSL group, while no significant change was observed in the CNIs group; however, discharge QMG scores and changes did not differ significantly between the groups. No differences were observed in AChR-Ab titers or the cumulative incidence of MM. All patients in both groups achieved MM or better status within one year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In this cohort of patients aged \u226570\u202fyears with MG, favorable outcomes were observed, regardless of PSL use. These findings highlight the clinical heterogeneity among older patients with MG and underscore the need for individualized treatment approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1853517","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:42:51Z","timestamp":1785300171000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The treatment with or without prednisolone in adults aged \u2265 70\u202fyears with myasthenia gravis: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Kazuo","family":"Iwasa","sequence":"first","affiliation":[{"name":"Department of Health and Medical Sciences, Ishikawa Prefectural Nursing University","place":["Kahoku, Japan"]},{"name":"Department of Neurology, Kanazawa University Graduate School of Medical Science","place":["Kanazawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kanazawa University Graduate School of Medical Science","place":["Kanazawa, Japan"]},{"name":"National Hospital Organization Kanazawa Medical Center","place":["Kanazawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Health Service Center, Kanazawa University","place":["Kanazawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeko","family":"Noguchi-Shinohara","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kanazawa Medical Center","place":["Kanazawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Ono","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kanazawa Medical Center","place":["Kanazawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e0274161","DOI":"10.1371\/journal.pone.0274161","article-title":"Two-step nationwide epidemiological survey of myasthenia gravis in Japan, 2018","volume":"17","author":"Yoshikawa","year":"2022","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","article-title":"Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis","volume":"19","author":"Salari","year":"2021","journal-title":"J Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.nmd.2023.02.013","article-title":"Clinical characteristics and prognosis of very late-onset myasthenia gravis in China","volume":"33","author":"Tang","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ensci.2016.02.004","article-title":"Late-onset myasthenia gravis is predisposed to become generalized in the elderly","volume":"2","author":"Sakai","year":"2016","journal-title":"eNeurologicalSci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"843523","DOI":"10.3389\/fneur.2022.843523","article-title":"Efficacy and safety of tacrolimus therapy for a single Chinese cohort with very-late-onset myasthenia gravis","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1277420","DOI":"10.3389\/fneur.2024.1277420","article-title":"Treatment strategies and treatment-related adverse events in MG according to the age of onset","volume":"15","author":"Moura","year":"2024","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1641701","DOI":"10.3389\/fneur.2025.1641701","article-title":"The short-term prognosis of very late-onset generalized myasthenia gravis: a single-center retrospective cohort study","volume":"16","author":"Liampas","year":"2025","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42466-020-00091-z","article-title":"Outcome measures and treatment effectiveness in late-onset myasthenia gravis","volume":"2","author":"Pasqualin","year":"2020","journal-title":"Neurol Res Pract"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"111586","DOI":"10.1016\/j.jocn.2025.111586","article-title":"Clinical heterogeneity, treatment patterns, and outcomes of advanced-age-onset myasthenia gravis in China: a retrospective cohort study","volume":"141","author":"Ji","year":"2025","journal-title":"J Clin Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s10072-024-07920-y","article-title":"Phenotypic patterns and response to immunotherapy in a group of very late onset myasthenia gravis: a single center study","volume":"46","author":"Vakrakou","year":"2025","journal-title":"Neurol Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mus.27369","article-title":"Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis","volume":"64","author":"Vijayan","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s40120-025-00796-w","article-title":"Use of corticosteroids in myasthenia gravis: expert opinion for daily management","volume":"14","author":"Mantegazza","year":"2025","journal-title":"Neurol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e933296","DOI":"10.12659\/MSM.933296","article-title":"Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Med Sci Monit"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e0126579","DOI":"10.1371\/journal.pone.0126579","article-title":"Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study","volume":"10","author":"Konno","year":"2015","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40520-021-01823-0","article-title":"Management of glucocorticoid-induced osteoporosis","volume":"33","author":"Messina","year":"2021","journal-title":"Aging Clin Exp Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/17446651.2020.1772051","article-title":"Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis","volume":"15","author":"Chiodini","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/01616412.2021.1948767","article-title":"Risk factors for potential drug-drug interactions in patients with myasthenia gravis","volume":"43","author":"Aleksi\u0107","year":"2021","journal-title":"Neurol Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol Clin"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.36185\/2532-1900-038","article-title":"Myasthenia gravis: MuSK MG, late-onset MG and ocular MG","volume":"39","author":"Deymeer","year":"2020","journal-title":"Acta Myol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","article-title":"Clinical characteristics and prognosis of myasthenia gravis in older people","volume":"48","author":"Evoli","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"ref26","first-page":"254","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume-title":"Ann N Y Acad Sci","author":"Ponseti","year":"2008"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"118074","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J Neurol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"110457","DOI":"10.1016\/j.clim.2025.110457","article-title":"The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients","volume":"274","author":"Zhang","year":"2025","journal-title":"Clin Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/bs.irn.2025.04.018","article-title":"Rescue therapy in myasthenia gravis","volume":"183","author":"Bril","year":"2025","journal-title":"Int Rev Neurobiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1007\/s00415-023-11925-6","article-title":"Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study","volume":"270","author":"Chanson","year":"2023","journal-title":"J Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.nmd.2021.02.010","article-title":"Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis","volume":"31","author":"Itani","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Yassamine","year":"2020","journal-title":"Artif Organs"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1853517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:43:07Z","timestamp":1785300187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1853517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":32,"alternative-id":["10.3389\/fneur.2026.1853517"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1853517","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1853517"}}